IP Library Granted Patent US 8,299,251
Granted Patent B2
US 8,299,251 · App. 12/994,950 · Granted Oct 30, 2012

Method for producing camptothecin derivatives

Assignees: Sichuan Xieli Pharmaceutical Co., Ltd.; MicroBiopharm Japan Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,299,251
App. No.
12/994,950
Granted
Oct 30, 2012
Kind
B2
Abstract

The invention offers a method of hydrogenating camptothecin in inert solvent in the presence of nickel catalyst, whereby selective hydrogenation of camptothecin can be very efficiently accomplished using the low-cost catalyst.

Claims (9)

1. A method comprising reduction of a compound represented by the following formula (I) to produce the corresponding 1,2,6,7-tetrahydro compound represented by the following formula (II), comprising a step of contacting a compound of the formula (I) with hydrogen in an inert solvent, in the presence of a nickel catalyst as a hydrogenation catalyst:

in the formulae, R stands for an atom or an atomic group selected from the group consisting of hydrogen atom and C 1 -C 6 alkyl groups.

2. A production method according to claim 1 , in which R is hydrogen atom.

3. A production method according to claim 1 , which is characterized in that the nickel catalyst is at least one member selected from the group consisting of metal nickel, reduced nickel, stabilized nickel, nickel-diatomaceous earth, Raney nickel, modified Raney nickel, nickel formate, Urushibara nickel, nickel borate, nickel oxide, nickel complex, nickel-copper-diatomaceous earth, nickel-zirconia-diatomaceous earth, nickel-alumina, nickel-silica-alumina, nickel-cobalt, nickel-copper-cobalt, nickel-iron, nickel-iron-cobalt, nickel-iron-phosphorus, nickel oxide-silica, nickel oxide-magnesium oxide-alumina and nickel oxide-molybdenum trioxide-alumina.

4. A production method according to claim 1 , which is characterized in that the nickel catalyst is Raney nickel, modified Raney nickel, or stabilized nickel.

5. A production method according to claim 1 , which is characterized in that the nickel catalyst is stabilized nickel.

6. A production method according to claim 2 , which is characterized in that the nickel catalyst is at least one member selected from the group consisting of metal nickel, reduced nickel, stabilized nickel, nickel-diatomaceous earth, Raney nickel, modified Raney nickel, nickel formate, Urushibara nickel, nickel borate, nickel oxide, nickel complex, nickel-copper-diatomaceous earth, nickel- zirconia-diatomaceous earth, nickel-alumina, nickel-silica-alumina, nickel-cobalt, nickel-copper-cobalt, nickel-iron, nickel-iron-cobalt, nickel-iron-phosphorus, nickel oxide-silica, nickel oxide-magnesium oxide-alumina and nickel oxide-molybdenum trioxide-alumina.

7. A production method according to claim 2 , which is characterized in that the nickel catalyst is Raney nickel, modified Raney nickel, or stabilized nickel.

8. A production method according to claim 2 , which is characterized in that the nickel catalyst is stabilized nickel.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2021
From: SANLI HOLDINGS CO., LTD.
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 058561/0528 →
CHANGE OF NAME Recorded Dec 14, 2021
From: MICROBIOPHARM JAPAN CO., LTD.
To: SANLI HOLDINGS CO., LTD.
Reel/Frame 058383/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2012
From: MERCIAN CORPORATION
To: MICROBIOPHARM JAPAN CO., LTD.
Reel/Frame 027791/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2010
From: TOYODA, ASAKO; NAGAI, HAZUKI; WANYOIKE, GEORGE NG'ANG'A
To: MERCIAN CORPORATION; SICHUAN XIELI PHARMACEUTICAL CO., LTD.
Reel/Frame 025447/0923 →
Priority Claims (1)
JP 2008-140942 · May 29, 2008 · national
Continuity (1)
Related Publication 20110112298A1 · May 12, 2011